You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
|
---|---|
Published in |
Clinical Cancer Research, March 2010
|
DOI | 10.1158/1078-0432.ccr-09-1611 |
Pubmed ID | |
Authors |
April A.N. Rose, Andrée-Anne Grosset, Zhifeng Dong, Caterina Russo, Patricia A. MacDonald, Nicholas R. Bertos, Yves St-Pierre, Ronit Simantov, Michael Hallett, Morag Park, Louis Gaboury, Peter M. Siegel |
Abstract |
Although the murine orthologue of glycoprotein nonmetastatic B (GPNMB), Osteoactivin, promotes breast cancer metastasis in an in vivo mouse model, its importance in human breast cancer is unknown. We have examined the significance of GPNMB expression as a prognostic indicator of recurrence and assessed its potential as a novel therapeutic target in breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 2 | 2% |
Malaysia | 1 | 1% |
France | 1 | 1% |
Australia | 1 | 1% |
Unknown | 94 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 17 | 17% |
Researcher | 17 | 17% |
Other | 11 | 11% |
Student > Postgraduate | 11 | 11% |
Student > Master | 11 | 11% |
Other | 13 | 13% |
Unknown | 19 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 23 | 23% |
Agricultural and Biological Sciences | 21 | 21% |
Biochemistry, Genetics and Molecular Biology | 15 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
Immunology and Microbiology | 3 | 3% |
Other | 8 | 8% |
Unknown | 23 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2021.
All research outputs
#1,647,769
of 22,665,794 outputs
Outputs from Clinical Cancer Research
#1,256
of 12,565 outputs
Outputs of similar age
#5,913
of 95,411 outputs
Outputs of similar age from Clinical Cancer Research
#8
of 118 outputs
Altmetric has tracked 22,665,794 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,565 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,411 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.